Cellectis S.A. Files 20-F/A Amendment
Ticker: CLLS · Form: 20-F/A · Filed: Mar 14, 2025 · CIK: 1627281
Sentiment: neutral
Topics: amendment, annual-report, biotech
TL;DR
Cellectis S.A. amended its 2024 annual report (20-F/A) on March 14, 2025.
AI Summary
Cellectis S.A. filed an amendment (20-F/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated March 14, 2025, is an amendment to their previous filings and pertains to their status as a public company. Cellectis S.A. is a biotechnology company focused on gene editing.
Why It Matters
This filing indicates an update or correction to Cellectis S.A.'s annual reporting, which is crucial for investors to have the most accurate and up-to-date information on the company's financial health and operations.
Risk Assessment
Risk Level: low — This filing is an amendment to an annual report and does not appear to contain new material financial information or significant operational changes.
Key Numbers
- 2024 — Fiscal Year End (The report covers the fiscal year ending on this date.)
- 20250314 — Filing Date (The amendment was filed on this date.)
Key Players & Entities
- Cellectis S.A. (company) — Filer of the 20-F/A amendment
- March 14, 2025 (date) — Date of filing the amendment
- December 31, 2024 (date) — Fiscal year end for the report
- 0001193125-25-054874 (filing_id) — Accession number for the filing
FAQ
What specific information is being amended in this 20-F/A filing?
The filing itself is an amendment (Amendment No. 1) to the annual report, indicating that previous information may have been corrected or supplemented, though the specific details of the amendment are not detailed in the provided header information.
What is the primary business of Cellectis S.A.?
Cellectis S.A. is in the business of 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' as indicated by its Standard Industrial Classification code [2836].
When was the original annual report for the fiscal year 2024 filed?
The provided text does not explicitly state the filing date of the original 20-F report for the fiscal year 2024, only that this is an amendment (20-F/A) filed on March 14, 2025.
What is the company's registered address?
Cellectis S.A.'s business and mail address is 8 RUE DE LA CROIX JARRY, PARIS, LLE-DE-FRANCE, 75013.
What type of securities does Cellectis S.A. have outstanding as of December 31, 2024?
As of December 31, 2024, Cellectis S.A. had ordinary shares, Class A Convertible Preferred Shares, and Class B Convertible Preferred Shares.
Filing Details
This Form 20-F/A (Form 20-F/A) was filed with the SEC on March 14, 2025 regarding Cellectis S.A. (CLLS).